Novartis's generics division Sandoz says Phase III results show its Neupogen biosimilar has a “similar safety and efficacy” profile as Amgen's branded biologic. The drugmaker said in a statement that the Phase-III Pioneer study showed that toggling between its biosimilar and Amgen's Neupogen “showed no impact on efficacy, safety or immunogenicity.” The FDA accepted Sandoz's application to review its filgrastim biosimilar in July.
Team Onyx awaits for your FIRING!!!
Team Onyx awaits for your FIRING!!!
Bye Bye Neupogen!
Aucun commentaire:
Enregistrer un commentaire